Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis
Conditions
Interventions
mycophenolate mofetil (CellCept)
placebo
Locations
43
United States
Sun City, Arizona, United States
Sacramento, California, United States
Miami, Florida, United States
Kansas City, Kansas, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Start Date
August 1, 2004
Completion Date
May 1, 2007
Last Updated
May 26, 2008
NCT06485232
NCT03165435
Lead Sponsor
Hoffmann-La Roche
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions